小霖妹子
2021-09-10
Pls like
After-Hours Stock Movers: IVERIC bio,Apellis Pharmaceuticals,Affirm and more
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
5
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":883835041,"tweetId":"883835041","gmtCreate":1631231987683,"gmtModify":1631890287390,"author":{"id":3579326417741698,"idStr":"3579326417741698","authorId":3579326417741698,"authorIdStr":"3579326417741698","name":"小霖妹子","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":9,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Pls like</p></body></html>","htmlText":"<html><head></head><body><p>Pls like</p></body></html>","text":"Pls like","highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/883835041","repostId":2166479623,"repostType":4,"repost":{"id":"2166479623","kind":"news","pubTimestamp":1631231042,"share":"https://www.laohu8.com/m/news/2166479623?lang=&edition=full","pubTime":"2021-09-10 07:44","market":"us","language":"en","title":"After-Hours Stock Movers: IVERIC bio,Apellis Pharmaceuticals,Affirm and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2166479623","media":"StreetInsider","summary":"After-Hours Stock Movers:\nIVERIC bio (NASDAQ: ISEE) 47.9% HIGHER; gains following data from Apellis\n","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/ISEE\">IVERIC bio</a> (NASDAQ: ISEE) 47.9% HIGHER; gains following data from Apellis</p>\n<p><a href=\"https://laohu8.com/S/APLS\">Apellis Pharmaceuticals, Inc.</a> (Nasdaq: APLS) 31.9% LOWER; reported top-line results from the Phase 3 DERBY and OAKS studies evaluating intravitreal pegcetacoplan, an investigational targeted C3 therapy, in 1,258 adults with geographic atrophy (GA) secondary to age-related macular degeneration (<a href=\"https://laohu8.com/S/AMD\">AMD</a>). OAKS met the primary endpoint for both monthly and every-other-month treatment with pegcetacoplan, demonstrating a significant reduction in GA lesion growth of 22% (p=0.0003) and 16% (p=0.0052), respectively, compared to pooled sham at 12 months. DERBY did not meet the primary endpoint of GA lesion growth, showing a reduction of 12% (p=0.0528) and 11% (p=0.0750) with monthly and every-other-month treatment, respectively, compared to pooled sham at 12 months.</p>\n<p><a href=\"https://laohu8.com/S/AFRM\">Affirm Holdings, Inc.</a> (NASDAQ: AFRM) 20.8% HIGHER; reported Q4 EPS of ($0.48), $0.19 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $261.8 million versus the consensus estimate of $225.29 million. Affirm Holdings, Inc. sees Q1 2022 revenue of $240-250 million, versus the consensus of $233.9 million. Affirm Holdings, Inc. sees FY2022 revenue of $1.16-1.19 billion, versus the consensus of $1.17 billion.</p>\n<p><a href=\"https://laohu8.com/S/KPLT\">Katapult Holdings, Inc.</a> (NASDAQ: KPLT) 12.2% HIGHER; gains on AFRM results.</p>\n<p><a href=\"https://laohu8.com/S/COOK\">Traeger, Inc.</a> (NYSE: COOK) 9.8% LOWER; reported Q2 EPS of ($0.05), versus $0.17 reported last year. Revenue for the quarter came in at $213 million, versus $153.2 million reported last year. Traeger, Inc. sees FY2021 revenue of $760-770 million. Adjusted EBITDA is expected to be between $103 million and $108 million</p>\n<p><a href=\"https://laohu8.com/S/CDR\">Cedar Realty Trust</a> (NYSE: CDR) 8.5% HIGHER; announced that its Board of Directors has initiated a dual-track process to review the Company's strategic alternatives in order to maximize shareholder value. As part of this process, Cedar is exploring, among other alternatives, a potential sale or merger involving the entire Company, and alternatively the potential sale of its core grocery-anchored shopping center portfolio and its mixed-use redevelopment projects.</p>\n<p><a href=\"https://laohu8.com/S/AOUT\">American Outdoor Brands</a> (NASDAQ: AOUT) 5.9% HIGHER; reported Q1 EPS of $0.48, $0.08 better than the analyst estimate of $0.40. Revenue for the quarter came in at $60.8 million versus the consensus estimate of $57.35 million. American Outdoor Brands sees FY2022 EPS of $2.02-$2.26, versus the consensus of $2.21. American Outdoor Brands sees FY2022 revenue of $280-295 million, versus the consensus of $291 million.</p>\n<p><a href=\"https://laohu8.com/S/SUMO\">Sumo Logic Inc.</a> (NASDAQ: SUMO) 6.3% LOWER; reported Q2 EPS of ($0.11), $0.03 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $58.8 million versus the consensus estimate of $56.69 million. Sumo Logic Inc. sees Q3 2022 EPS of ($0.14), versus the consensus of ($0.15). Sumo Logic Inc. sees Q3 2022 revenue of $60.3-61.3 million, versus the consensus of $60.05 million. Sumo Logic Inc. sees FY2022 EPS of ($0.52)-($0.51), versus the consensus of ($0.56). Sumo Logic Inc. sees FY2022 revenue of $236.8-238.8 million, versus the consensus of $235.02 million</p>\n<p><a href=\"https://laohu8.com/S/CANO\">Cano Health</a> (NYSE: CANO) 2.2% HIGHER; Cowen initiates coverage with an Outperform rating and a price target of $18.00.</p>\n<p><a href=\"https://laohu8.com/S/ZUMZ\">Zumiez, Inc.</a> (NASDAQ: ZUMZ) 5.3% LOWER; reported Q2 EPS of $0.94, $0.16 better than the analyst estimate of $0.78. Revenue for the quarter came in at $268.7 million versus the consensus estimate of $279.79 million.</p>\n<p><a href=\"https://laohu8.com/S/CLOV\">Clover Health</a> (NASDAQ: CLOV) 2.6% LOWER; Cowen analyst Gary Taylor initiates coverage with an Underperform rating and a price target of $7.00.</p>\n<p><a href=\"https://laohu8.com/S/EDIT\">Editas Medicine</a> (NASDAQ: EDIT) 2.2% HIGHER; Oppenheimer upgraded from Perform to Outperform with a price target of $80.00 (from $42.00).</p>\n<p><a href=\"https://laohu8.com/S/TTWO\">Take-Two Interactive Software</a>, Inc. (NASDAQ: TTWO) 2.5% LOWER; reiterated its outlook for its fiscal year 2022, ending March 31, 2022, which was originally provided on May 18, 2021 and reiterated on August 2, 2021. The Company’s wholly-owned label, Rockstar Games, has announced that the expanded and enhanced versions of Grand Theft Auto V and Grand Theft Auto Online for PlayStation 5 and Xbox Series X|S, which had been planned for release on November 11, 2021, are now planned to launch in March 2022 to allow additional time to further polish the final products.</p>\n<p><a href=\"https://laohu8.com/S/ZS\">Zscaler</a> (NASDAQ: ZS) 2.4% HIGHER; reported Q4 EPS of $0.14, $0.05 better than the analyst estimate of $0.09. Revenue for the quarter came in at $197.1 million versus the consensus estimate of $186.82 million. Zscaler sees Q1 2022 EPS of $0.12, versus the consensus of $0.12. Zscaler sees Q1 2022 revenue of $210-212 million, versus the consensus of $199.7 million. Zscaler sees FY2022 EPS of $0.52-$0.56, versus the consensus of $0.56. Zscaler sees FY2022 revenue of $940-950 million, versus the consensus of $905.8 million.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: IVERIC bio,Apellis Pharmaceuticals,Affirm and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: IVERIC bio,Apellis Pharmaceuticals,Affirm and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-10 07:44 GMT+8 <a href=https://www.streetinsider.com/dr/news.php?id=18924599><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nIVERIC bio (NASDAQ: ISEE) 47.9% HIGHER; gains following data from Apellis\nApellis Pharmaceuticals, Inc. (Nasdaq: APLS) 31.9% LOWER; reported top-line results from the Phase 3...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18924599\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"APLS":"Apellis Pharmaceuticals Inc.","ISEE":"IVERIC bio Inc","KPLT":"Katapult Holdings, Inc.","AFRM":"Affirm Holdings, Inc.","COOK":"Traeger Inc. (TGPX Holdings I LLC)","ZUMZ":"Zumiez Inc"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18924599","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166479623","content_text":"After-Hours Stock Movers:\nIVERIC bio (NASDAQ: ISEE) 47.9% HIGHER; gains following data from Apellis\nApellis Pharmaceuticals, Inc. (Nasdaq: APLS) 31.9% LOWER; reported top-line results from the Phase 3 DERBY and OAKS studies evaluating intravitreal pegcetacoplan, an investigational targeted C3 therapy, in 1,258 adults with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). OAKS met the primary endpoint for both monthly and every-other-month treatment with pegcetacoplan, demonstrating a significant reduction in GA lesion growth of 22% (p=0.0003) and 16% (p=0.0052), respectively, compared to pooled sham at 12 months. DERBY did not meet the primary endpoint of GA lesion growth, showing a reduction of 12% (p=0.0528) and 11% (p=0.0750) with monthly and every-other-month treatment, respectively, compared to pooled sham at 12 months.\nAffirm Holdings, Inc. (NASDAQ: AFRM) 20.8% HIGHER; reported Q4 EPS of ($0.48), $0.19 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $261.8 million versus the consensus estimate of $225.29 million. Affirm Holdings, Inc. sees Q1 2022 revenue of $240-250 million, versus the consensus of $233.9 million. Affirm Holdings, Inc. sees FY2022 revenue of $1.16-1.19 billion, versus the consensus of $1.17 billion.\nKatapult Holdings, Inc. (NASDAQ: KPLT) 12.2% HIGHER; gains on AFRM results.\nTraeger, Inc. (NYSE: COOK) 9.8% LOWER; reported Q2 EPS of ($0.05), versus $0.17 reported last year. Revenue for the quarter came in at $213 million, versus $153.2 million reported last year. Traeger, Inc. sees FY2021 revenue of $760-770 million. Adjusted EBITDA is expected to be between $103 million and $108 million\nCedar Realty Trust (NYSE: CDR) 8.5% HIGHER; announced that its Board of Directors has initiated a dual-track process to review the Company's strategic alternatives in order to maximize shareholder value. As part of this process, Cedar is exploring, among other alternatives, a potential sale or merger involving the entire Company, and alternatively the potential sale of its core grocery-anchored shopping center portfolio and its mixed-use redevelopment projects.\nAmerican Outdoor Brands (NASDAQ: AOUT) 5.9% HIGHER; reported Q1 EPS of $0.48, $0.08 better than the analyst estimate of $0.40. Revenue for the quarter came in at $60.8 million versus the consensus estimate of $57.35 million. American Outdoor Brands sees FY2022 EPS of $2.02-$2.26, versus the consensus of $2.21. American Outdoor Brands sees FY2022 revenue of $280-295 million, versus the consensus of $291 million.\nSumo Logic Inc. (NASDAQ: SUMO) 6.3% LOWER; reported Q2 EPS of ($0.11), $0.03 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $58.8 million versus the consensus estimate of $56.69 million. Sumo Logic Inc. sees Q3 2022 EPS of ($0.14), versus the consensus of ($0.15). Sumo Logic Inc. sees Q3 2022 revenue of $60.3-61.3 million, versus the consensus of $60.05 million. Sumo Logic Inc. sees FY2022 EPS of ($0.52)-($0.51), versus the consensus of ($0.56). Sumo Logic Inc. sees FY2022 revenue of $236.8-238.8 million, versus the consensus of $235.02 million\nCano Health (NYSE: CANO) 2.2% HIGHER; Cowen initiates coverage with an Outperform rating and a price target of $18.00.\nZumiez, Inc. (NASDAQ: ZUMZ) 5.3% LOWER; reported Q2 EPS of $0.94, $0.16 better than the analyst estimate of $0.78. Revenue for the quarter came in at $268.7 million versus the consensus estimate of $279.79 million.\nClover Health (NASDAQ: CLOV) 2.6% LOWER; Cowen analyst Gary Taylor initiates coverage with an Underperform rating and a price target of $7.00.\nEditas Medicine (NASDAQ: EDIT) 2.2% HIGHER; Oppenheimer upgraded from Perform to Outperform with a price target of $80.00 (from $42.00).\nTake-Two Interactive Software, Inc. (NASDAQ: TTWO) 2.5% LOWER; reiterated its outlook for its fiscal year 2022, ending March 31, 2022, which was originally provided on May 18, 2021 and reiterated on August 2, 2021. The Company’s wholly-owned label, Rockstar Games, has announced that the expanded and enhanced versions of Grand Theft Auto V and Grand Theft Auto Online for PlayStation 5 and Xbox Series X|S, which had been planned for release on November 11, 2021, are now planned to launch in March 2022 to allow additional time to further polish the final products.\nZscaler (NASDAQ: ZS) 2.4% HIGHER; reported Q4 EPS of $0.14, $0.05 better than the analyst estimate of $0.09. Revenue for the quarter came in at $197.1 million versus the consensus estimate of $186.82 million. Zscaler sees Q1 2022 EPS of $0.12, versus the consensus of $0.12. Zscaler sees Q1 2022 revenue of $210-212 million, versus the consensus of $199.7 million. Zscaler sees FY2022 EPS of $0.52-$0.56, versus the consensus of $0.56. Zscaler sees FY2022 revenue of $940-950 million, versus the consensus of $905.8 million.","news_type":1},"isVote":1,"tweetType":1,"viewCount":200,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":7,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/883835041"}
精彩评论